Vector BioMed Capacity Update October 2025: Cell & Gene Therapy

Vector BioMed (VBM) is a state-of-the-art CVDMO (Contract Vector Development and Manufacturing Organization) and public benefit corporation transforming gene therapy product development. An efficient manufacturing process provides high titer and high quality at an affordable price. With low costs and under the shortest possible timelines for lentiviral vector (LV) production and delivery, VBM enables global access to LV. Services include flexible and standardized turn-key solutions for vector design, vector optimization, pre-clinical manufacturing, and CGMP manufacturing. VBM supports biopharma, institutions, and global health systems to move from concept to commercialization. Simplifying development and bridging innovation to cure.

Breaking away from legacy lentiviral vector (LV) platforms, development, and manufacturing paradigms, Vector BioMed (VBM) specializes in rapid tracks to implement LV into cell manufacturing workflows. Founded on LV design, manufacturing excellence, and ultimately purpose, VBM and the LENTIVERSE™ technology platform provide a full suite of tools to enable those looking to quickly deliver state-of-the-art therapies as well as those developing next-generation products.